Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J Wallis

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|November 3, 1998
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertensionE J Wallis, L E Ramsay, J Hettiarachchi
British Journal of Clinical Pharmacology|October 27, 2001
Statins for primary prevention: at what coronary risk is safety assured?P R Jackson, E J Wallis, I U Haq, et al.
British Journal of Clinical Pharmacology|December 3, 1999
Enhanced cholesterol reduction by simvastatin in diltiazem-treated patientsK R Yeo, W W Yeo, E J Wallis, et al.
QJM : Monthly Journal of the Association of Physicians|January 11, 2000
Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methodsI U Haq, L E Ramsay, P R Jackson, et al.
American Journal of Hypertension|July 9, 1998
The rationale for differing national recommendations for the treatment of hypertensionL E Ramsay, E J Wallis, W W Yeo, et al.
Journal of Hypertension|May 2, 2001
Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validationE J Wallis, L E Ramsay, I U Haq, et al.
Heart (British Cardiac Society)|February 17, 2001
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsP S Sanmuganathan, P Ghahramani, P R Jackson, et al.
Heart (British Cardiac Society)|April 30, 1999
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk menI U Haq, L E Ramsay, W W Yeo, et al.
Journal of Hypertension|December 23, 1999
Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension managementI U Haq, E J Wallis, P R Jackson, et al.
Heart (British Cardiac Society)|August 22, 2001
Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health surveyI U Haq, L E Ramsay, E J Wallis, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|November 3, 1998
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertensionE J Wallis, L E Ramsay, J Hettiarachchi
British Journal of Clinical Pharmacology|October 27, 2001
Statins for primary prevention: at what coronary risk is safety assured?P R Jackson, E J Wallis, I U Haq, et al.
British Journal of Clinical Pharmacology|December 3, 1999
Enhanced cholesterol reduction by simvastatin in diltiazem-treated patientsK R Yeo, W W Yeo, E J Wallis, et al.
QJM : Monthly Journal of the Association of Physicians|January 11, 2000
Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methodsI U Haq, L E Ramsay, P R Jackson, et al.
American Journal of Hypertension|July 9, 1998
The rationale for differing national recommendations for the treatment of hypertensionL E Ramsay, E J Wallis, W W Yeo, et al.
Journal of Hypertension|May 2, 2001
Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validationE J Wallis, L E Ramsay, I U Haq, et al.
Heart (British Cardiac Society)|February 17, 2001
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsP S Sanmuganathan, P Ghahramani, P R Jackson, et al.
Heart (British Cardiac Society)|April 30, 1999
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk menI U Haq, L E Ramsay, W W Yeo, et al.
Journal of Hypertension|December 23, 1999
Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension managementI U Haq, E J Wallis, P R Jackson, et al.
Heart (British Cardiac Society)|August 22, 2001
Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health surveyI U Haq, L E Ramsay, E J Wallis, et al.
Pageof 2